PharmaVitae interviewed a US-based KOL on pipeline and marketed drugs for type 2 diabetes and non-alcoholic steatohepatitis (NASH). The topics discussed include: prescribing trends, payer coverage, pricing and reimbursement, late-stage clinical trials, and regulatory updates

If you are a KOL Insight Subscriber, please access the interview from our KOL Insight portal (Subscribers only).

Biomedtracker will be offering KOL Reports and Physician Pulse Surveys for purchase a la carte, or access to all reports and surveys can be purchased as a subscription to KOL Insight. For more information on KOL Insight subscription, please email Biomedtracker or call Biomedtracker Client Services at (858) 200-2357.